Evenity market seen growing on osteoporosis demand and better screening

The Business Research Company says the Evenity market is set for steady growth as osteoporosis rates rise, especially among postmenopausal women at fracture risk. North America led the market in 2025, while Europe is projected to grow fastest as awareness, screening and access to biologic therapies improve.

Why it matters: - Evenity targets osteoporosis in postmenopausal women at high risk of fractures, so market growth tracks a large and costly public health need. - Fragility fractures drive major healthcare spending, which supports demand for treatments that can reduce fracture risk. - The market is also benefiting from broader adoption of biologic and anabolic osteoporosis therapies.

What happened: - The Business Research Company released a new analysis of the Evenity market on Nov. 4, 2026. - The report says North America held the largest Evenity market share in 2025. - The report projects Europe will post the fastest growth during the forecast period. - The report includes coverage of Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The company offers a free sample of the Evenity market report. - The company also provides the full Evenity market report.

The details: - Evenity, or romosozumab, is a biologic drug for osteoporosis in postmenopausal women at high fracture risk. - The drug blocks sclerostin, which helps stimulate new bone formation and reduce bone loss. - Evenity is typically given as a monthly subcutaneous injection for up to 12 months. - Patients usually move to another osteoporosis therapy after Evenity to help maintain bone health. - Market growth has been supported by an aging female population, widespread postmenopausal osteoporosis and the limits of antiresorptive drugs. - The report says increasing awareness of bone health, better screening, wider use of biologics, better access for older adults and favorable reimbursement are helping future growth. - The report also points to higher use of anabolic osteoporosis therapies, stronger focus on fracture prevention and preference for monthly injectable regimens. - In February 2023, the UK's Royal Osteoporosis Society said fragility fractures cost the NHS about $5.89 billion a year, with hip fractures accounting for $2.62 billion. - In July 2024, ASGCT reported a 25% increase in gene therapy trials started in the second quarter of 2024 versus the prior quarter, reflecting faster drug development momentum across biotech. - The UK's Office for National Statistics said healthcare spending rose 5.6% in nominal terms from 2022 to 2023, after 0.9% growth in 2022.

Between the lines: - Evenity's growth story is less about a single drug and more about a larger shift toward prevention, earlier diagnosis and therapies that aim to lower fracture risk before costly injuries happen. - The regional split suggests mature markets are absorbing current demand, while Europe's forecast growth points to room for improved screening and treatment uptake. - The report's emphasis on reimbursement and access signals that pricing and coverage may matter as much as clinical demand.

What's next: - The market is expected to benefit from continued osteoporosis screening and broader use of biologic treatment options. - Growth could accelerate if healthcare systems expand access for older adults and keep reimbursement supportive of fracture prevention. - The Business Research Company says future market trends will center on monthly injectables, shorter treatment regimens and integrated bone care.

The bottom line: - Evenity sits in a market lifted by aging populations, rising fracture costs and stronger appetite for targeted bone therapies.